NeuroDefend, a novel Chinese medicine, attenuates amyloid-β and tau pathology in experimental Alzheimer's disease models

Ashok IYASWAMY, Senthil Kumar Krishnamoorthi, Juxian SONG, Chuanbin YANG, Venkatapathy Kaliyamoorthy, Huan Zhang, Sravan G. Sreenivasmurthy, Sandeep Malampati, Zi Ying Wang, Zhou Zhu, Chun Kit Benjamin TONG, King-Ho CHEUNG, Jia Hong Lu, S S Kumar DURAIRAJAN, Min LI*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder. Amyloid-β (Aβ) and hyper-phosphorylated tau accumulation are accountable for the progressive neuronal loss and cognitive impairments usually observed in AD. Currently, medications for AD offer moderate symptomatic relief but fail to cure the disease; hence development of effective and safe drugs is urgently needed for AD treatment. In this study, we investigated a Chinese medicine (CM) formulation named NeuroDefend (ND), for reducing amyloid β (Aβ) and tau pathology in transgenic AD mice models. Regular oral administration of ND improved cognitive function and memory in 3XTg-AD and 5XFAD mice. In addition, ND reduced beta-amyloid precursor protein (APP), APP C-terminal fragments (CTF-β/α), Aβ and 4G8 positive Aβ burden in 3XTg-AD and 5XFAD mice. Furthermore, ND efficiently reduced the levels of insoluble phospho-tau protein aggregates and AT8 positive phospho tau neuron load in 3XTg-AD mice. Hence, ND could be a promising candidate for the treatment of AD in humans.

Original languageEnglish
Pages (from-to)132-146
Number of pages15
JournalJournal of Food and Drug Analysis
Volume28
Issue number1
DOIs
Publication statusPublished - Jan 2020

Scopus Subject Areas

  • Food Science
  • Pharmacology

User-Defined Keywords

  • Alzheimer's disease
  • Aβ-plaque
  • Chinese medicine
  • NeuroDefend
  • Neurofibrillary tangles

Fingerprint

Dive into the research topics of 'NeuroDefend, a novel Chinese medicine, attenuates amyloid-β and tau pathology in experimental Alzheimer's disease models'. Together they form a unique fingerprint.

Cite this